The U.S. National Institutes of Health is restarting a coordinated research effort aimed at spotting and understanding dangerous new pathogens before they spread widely—yet the revived program is arriving with limits that many scientists say undermine its core purpose.
The rebooted network is framed as part of NIH’s broad public-health mandate: generating fundamental knowledge about living systems and applying it to prevent disease, reduce disability and save lives. NIH, the nation’s medical research agency within the U.S. Department of Health and Human Services, supports this mission through a sprawling structure of 27 institutes and centers, alongside intramural labs and nationwide grants that fund everything from basic biology to clinical trials. In recent years, NIH has also emphasized AI, data science, digital health and other emerging technologies as tools to accelerate discovery.
But researchers who work at the human–animal interface—where many viral spillovers begin—say the new iteration of the emerging-disease network is accompanied by restrictions that sharply curtail proactive wildlife surveillance, including limits that amount to a ban on searching for novel viruses in wild animals. Critics argue that this is not a technical detail but a defining choice that could transform an early-warning system into a reactive one.
At the heart of the dispute is a clash between two scientific strategies. One approach focuses on monitoring known threats: testing animals and people for viruses already recognized as risky, mapping their spread, and studying how they evolve. The other casts a wider net, sampling wildlife and ecosystems to catalog previously unknown viruses and assess which ones might have the ingredients to infect humans. The second strategy is contentious—politically, ethically and in terms of biosafety—but many experts regard it as central to preparing for pandemics that start with surprises.
Scientists involved in zoonotic research say a “don’t look for new viruses” rule is difficult to reconcile with the logic of emergence. New outbreaks often involve pathogens that were not on anyone’s watchlist. If researchers cannot characterize viral diversity in wildlife, they argue, models of spillover risk become less reliable, diagnostics may be slower to develop, and vaccine and therapeutic research may lose lead time.
NIH’s supporters counter that the agency is trying to navigate an unusually charged landscape—one shaped by concerns about biosafety, dual-use research and the possibility that some types of pathogen work could be misused or lead to accidents. In this view, the network’s revival is not a retreat from preparedness but an attempt to rebuild it under guardrails that can command broader confidence. Even so, many investigators say the current guardrails appear blunt, leaving them uncertain about what is permissible, how samples can be handled, and which discovery-oriented questions are now off limits.
The restrictions also come at a moment when NIH is promoting new computational and data-driven methods that could, in principle, strengthen early-warning science. Across NIH’s portfolio, researchers are using sophisticated modeling to probe complex biological questions, including how variables such as sex can influence treatment response—an area where NIH-backed studies are testing new computational approaches to extract patterns that traditional trials may miss. Scientists say similar toolkits—machine learning, genomic analytics and integrated datasets—are increasingly important in outbreak research as well, helping teams connect animal surveillance, viral genetics and human case data.
Another strand of NIH-funded work points to how rapidly biomedical science is evolving beyond traditional lab workflows. In separate NIH-supported research, engineers have developed devices that translate patterns of brain activity into digital outputs, illustrating how physiological signals can be converted into actionable information. Neuroscientists, meanwhile, have reported evidence that depression is associated with disrupted neuron formation in a memory-linked brain region—findings that underscore how deeply biology can shape health outcomes and how much remains unknown even in well-studied diseases. For emerging infections, researchers argue, that same recognition of “unknowns” is precisely why broad discovery—paired with careful oversight—matters.
NIH’s wider ecosystem may ultimately determine whether the revived network thrives despite the controversy. The agency curates biomedical data repositories, funds open-access publishing and maintains key databases that allow researchers to cross-link genetics, clinical outcomes and prior literature. These platforms could help standardize outbreak-relevant datasets and enable faster, more transparent analyses—if the data exist to begin with.
For now, the program’s revival is being greeted with a mixture of relief and frustration: relief that the U.S. is reinvesting in coordinated preparedness research, frustration that a flagship effort to understand emerging disease may be constrained from investigating emergence at its source.
As one researcher involved in pathogen discovery put it in interviews reflecting the broader sentiment in the field: it is hard to build a smoke detector if you are not allowed to look for smoke.
Why it matters
Most new infectious threats to humans start in animals, and early detection can buy precious time for diagnostics, vaccines and public-health response. A network designed to study emergence could strengthen preparedness—but only if its rules align with the scientific reality of how novel pathogens appear. How NIH balances safety, public trust and discovery will shape whether the next spillover is recognized early or only after hospitals begin to fill.